Literature DB >> 17972036

Immune agents for the treatment of Devic's neuromyelitis optica.

R Bergamaschi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17972036     DOI: 10.1007/s10072-007-0828-7

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  18 in total

Review 1.  Devic's neuromyelitis optica: clinical features and prognostic factors.

Authors:  R Bergamaschi; A Ghezzi
Journal:  Neurol Sci       Date:  2004-11       Impact factor: 3.307

2.  Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment.

Authors:  F Falcini; S Trapani; L Ricci; M Resti; G Simonini; M de Martino
Journal:  Rheumatology (Oxford)       Date:  2006-04-25       Impact factor: 7.580

3.  Rituxan warning.

Authors: 
Journal:  FDA Consum       Date:  2007 Mar-Apr

4.  NMO-IgG in the diagnosis of neuromyelitis optica.

Authors:  S Jarius; D Franciotta; R Bergamaschi; H Wright; E Littleton; J Palace; R Hohlfeld; A Vincent
Journal:  Neurology       Date:  2007-02-07       Impact factor: 9.910

5.  Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG).

Authors:  Jacqueline Bakker; Luanne Metz
Journal:  Can J Neurol Sci       Date:  2004-05       Impact factor: 2.104

6.  Devic's neuromyelitis optica: a clinicopathological study of 8 patients.

Authors:  R N Mandler; L E Davis; D R Jeffery; M Kornfeld
Journal:  Ann Neurol       Date:  1993-08       Impact factor: 10.422

7.  A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.

Authors:  Claudia F Lucchinetti; Raul N Mandler; Dorian McGavern; Wolfgang Bruck; Gerald Gleich; Richard M Ransohoff; Corinna Trebst; Brian Weinshenker; Dean Wingerchuk; Joseph E Parisi; Hans Lassmann
Journal:  Brain       Date:  2002-07       Impact factor: 13.501

8.  Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease).

Authors:  M Capobianco; S Malucchi; A di Sapio; F Gilli; A Sala; R Bottero; F Marnetto; C Doriguzzi Bozzo; A Bertolotto
Journal:  Neurol Sci       Date:  2007-08-10       Impact factor: 3.307

9.  Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor.

Authors:  Tjalf Ziemssen; Tania Kümpfel; Wolfgang E F Klinkert; Oliver Neuhaus; Reinhard Hohlfeld
Journal:  Brain       Date:  2002-11       Impact factor: 13.501

Review 10.  Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature.

Authors:  S G Freim Wahl; M R Folvik; S H Torp
Journal:  Clin Neuropathol       Date:  2007 Mar-Apr       Impact factor: 1.368

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.